عرض بسيط للتسجيلة

المؤلفAyoub, H.H.
المؤلفAyoub, Houssein H.
المؤلفChemaitelly, Hiam
المؤلفMakhoul, Monia
المؤلفAl Kanaani, Zaina
المؤلفAl Kuwari, Einas
المؤلفButt, Adeel A.
المؤلفCoyle, Peter
المؤلفJeremijenko, Andrew
المؤلفKaleeckal, Anvar Hassan
المؤلفLatif, Ali Nizar
المؤلفShaik, Riyazuddin Mohammad
المؤلفAbdul Rahim, Hanan F.
المؤلفNasrallah, Gheyath K.
المؤلفYassine, Hadi M.
المؤلفAl Kuwari, Mohamed G.
المؤلفAl Romaihi, Hamad Eid
المؤلفAl-Thani, Mohamed H.
المؤلفBertollini, Roberto
المؤلفAl Khal, Abdullatif
المؤلفAbu-Raddad, Laith J.
تاريخ الإتاحة2021-10-20T09:45:33Z
تاريخ النشر2021-04-01
اسم المنشورBMJ Innovations
المعرّفhttp://dx.doi.org/10.1136/bmjinnov-2021-000677
الاقتباسAyoub HH, Chemaitelly H, Makhoul M, et alEpidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analysesBMJ Innovations 2021;7:327-336.
الرقم المعياري الدولي للكتاب20558074
معرّف المصادر الموحدhttp://hdl.handle.net/10576/24586
الملخصBackground Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient antibody status, that is by exposure status, using Qatar as an example. Methods Vaccination impact (defined as the reduction in infection incidence and the number of vaccinations needed to avert one infection or one adverse disease outcome) was assessed under different scale-up scenarios using a deterministic meta-population mathematical model describing SARS-CoV-2 transmission and disease progression in the presence of vaccination. Results For a vaccine that protects against infection with an efficacy of 95%, half as many vaccinations were needed to avert one infection, disease outcome or death by prioritising antibody-negative individuals for vaccination. Prioritisation by antibody status reduced incidence at a faster rate and led to faster elimination of infection and return to normalcy. Further prioritisation by age group amplified the gains of prioritisation by antibody status. Gains from prioritisation by antibody status were largest in settings where the proportion of the population already infected at the commencement of vaccination was 30%-60%. For a vaccine that only protects against disease and not infection, vaccine impact was reduced by half, whether this impact was measured in terms of averted infections or disease outcomes, but the relative gains from using antibody status to prioritise vaccination recipients were similar. Conclusions Major health and economic gains can be achieved more quickly by prioritizing those who are antibody-negative while doses of the vaccine remain in short supply.
راعي المشروعThis study received support from the Biomedical Research Program, and the Biostatistics, Epidemiology, and Biomathematics Research Core, all at Weill Cornell MedicineQatar, as well as support provided by the Ministry of Public Health and Hamad Medical Corporation. The developed mathematical models were made possible by NPRP grant number 9-040-3-008 (principal investigator: LJA-R) and NPRP grant number 12S-0216-190094 (principal investigator: LJA-R) from the Qatar National Research Fund (a member of Qatar Foundation; https://www.qnrf.org).
اللغةen
الناشرBMJ Publishing Group
الموضوعcommunicable diseases
COVID-19
public health
vaccination
العنوانEpidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses
النوعArticle
الصفحات327-336
رقم العدد2
رقم المجلد7
ESSN2055-642X
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة